Literature DB >> 1838996

Niacinamide pretreatment reduces microvesicle formation in hairless guinea pigs cutaneously exposed to sulfur mustard.

J J Yourick1, C R Clark, L W Mitcheltree.   

Abstract

It has been proposed that sulfur mustard (HD) may indirectly activate poly(ADP-ribose) polymerase (PADPRP) by alkylating cellular DNA (Papirmeister et al., 1985). Activation of PADPRP results in the depletion of cellular NAD+, which initiates a series of biochemical processes that have been proposed to culminate in blister formation. Preventing PADPRP activation and NAD+ depletion should inhibit blister formation. Niacinamide is both an inhibitor of PADPRP and a precursor for NAD+ synthesis. The present study was undertaken to determine whether niacinamide can protect against HD-induced microvesication in cutaneously exposed hairless guinea pigs. Each site was exposed to HD for 8 min by means of a vapor cup. Niacinamide (750 mg/kg, ip) given as a 30-min pretreatment inhibited microvesicle formation by 50% after HD application. However, niacinamide given 2 hr after HD application did not reduce microvesicle formation. There was no benefit when niacinamide was given as both a pretreatment and treatment when compared to niacinamide given only as a pretreatment. The reduction in microvesication 24 hr after HD did not correlate with skin NAD+ content. Niacinamide did not reduce the degree of erythema or edema. Ballooning degeneration of basal epidermal cells was present in some niacinamide pretreated HD exposure sites. These results suggest that niacinamide may only be effective as a pretreatment compound to reduce the incidence of HD-induced microvesicle formation. Maintenance of skin NAD+ content may not be solely responsible for inhibiting microvesicle formation and inhibition of PADPRP may be of greater importance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1838996     DOI: 10.1016/0272-0590(91)90203-g

Source DB:  PubMed          Journal:  Fundam Appl Toxicol        ISSN: 0272-0590


  9 in total

1.  Inhibition of sulfur mustard-increased protease activity by niacinamide, N-acetyl-L-cysteine or dexamethasone.

Authors:  F M Cowan; C A Broomfield; W J Smith
Journal:  Cell Biol Toxicol       Date:  1992 Apr-Jun       Impact factor: 6.691

Review 2.  Putative roles of inflammation in the dermatopathology of sulfur mustard.

Authors:  F M Cowan; C A Broomfield
Journal:  Cell Biol Toxicol       Date:  1993 Jul-Sep       Impact factor: 6.691

Review 3.  Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2.

Authors:  Polina A Egorova; Ilya B Bezprozvanny
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

4.  Sulfur mustard-increased proteolysis following in vitro and in vivo exposures.

Authors:  F M Cowan; J J Yourick; C G Hurst; C A Broomfield; W J Smith
Journal:  Cell Biol Toxicol       Date:  1993 Jul-Sep       Impact factor: 6.691

5.  Effects of specific inhibitors of cellular functions on sulfur mustard-induced cell death.

Authors:  E T Clayson; S A Kelly; H L Meier
Journal:  Cell Biol Toxicol       Date:  1993 Apr-Jun       Impact factor: 6.691

6.  Wound healing of cutaneous sulfur mustard injuries: strategies for the development of improved therapies.

Authors:  John S Graham; Robert P Chilcott; Paul Rice; Stephen M Milner; Charles G Hurst; Beverly I Maliner
Journal:  J Burns Wounds       Date:  2005-01-05

7.  Signaling molecules in sulfur mustard-induced cutaneous injury.

Authors:  Albert L Ruff; James F Dillman
Journal:  Eplasty       Date:  2007-11-27

8.  Comparative evaluation of some flavonoids and tocopherol acetate against the systemic toxicity induced by sulphur mustard.

Authors:  R Vijayaraghavan; Anshoo Gautam; Manoj Sharma; H T Satish; S C Pant; K Ganesan
Journal:  Indian J Pharmacol       Date:  2008-06       Impact factor: 1.200

9.  Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo.

Authors:  Feng Liu; Ning Jiang; Zhi-Yong Xiao; Jun-Ping Cheng; Yi-Zhou Mei; Pan Zheng; Li Wang; Xiao-Rui Zhang; Xin-Bo Zhou; Wen-Xia Zhou; Yong-Xiang Zhang
Journal:  PeerJ       Date:  2016-04-04       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.